Loading clinical trials...
Loading clinical trials...
A LOW-INTERVENTIONAL LONGITUDINAL STUDY OF AN ELECTRONIC SICKLE CELL DISEASE PATIENT REPORTED OUTCOMES IN ADULT PARTICIPANTS AGED ≥18 YEARS OF AGE ON AND OFF HYDROXYUREA
Conditions
Interventions
Electronic Diary
Locations
5
United States
Foundation for Sickle Cell Disease Research
Hollywood, Florida, United States
Mid-Atlantic Permanente Medical Group Largo Medical Center
Largo, Maryland, United States
Mid-Atlantic Permanente Medical Group Largo Medical Center
Upper Marlboro, Maryland, United States
Sanguine Biosciences, Inc.
Waltham, Massachusetts, United States
Cohen Children's Medical Center
New Hyde Park, New York, United States
Start Date
February 10, 2022
Primary Completion Date
June 24, 2024
Completion Date
June 24, 2024
Last Updated
July 16, 2024
NCT05170412
NCT06526117
NCT06665997
NCT07431398
NCT07222475
NCT05377372
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions